Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) price closed lower on Friday, April 12, dropping -7.16% below its previous close.
A look at the daily price movement shows that the last close reads $48.03. The company’s 5Y monthly beta was ticking 0.62. Taking into account the 52-week price action we note that the stock hit a 52-week high of $49.58 and 52-week low of $15.66. The stock added 10.10% on its value in the past month.
Crinetics Pharmaceuticals Inc, which has a market valuation of $3.47 billion, is expected to release its quarterly earnings report May 02, 2024 – May 06, 2024.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give CRNX a short term outlook of 50% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Buy, while an average of long term indicators are currently assigning the stock as 100% Buy.
The overview shows that CRNX’s price is at present -0.28% off the SMA20 and 7.37% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 50.61, with weekly volatility standing at 5.55%. The indicator jumps to 5.94% when calculated based on the past 30 days. Crinetics Pharmaceuticals Inc (NASDAQ:CRNX)’s beta value is holding at 0.62, while the average true range (ATR) indicator is currently reading 2.67. An analysis of the Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock in terms of its daily trading volume indicates that the 3-month average is 800.95K.
Current records show that the company has 77.93M in outstanding shares. The insiders’ percentage holdings are 7.43% of outstanding shares while the percentage share held by institutions stands at 89.34%. But the 25.32% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
